Table 1.

Clinicopathological characteristics in responders and non-responders.

		Responder (n = 25)	Non-responder (n = 118)	Response rate (%)	P value
Age (years)	<70	8	51	13.6	0.30
	≥70	17	67	20.2
Sex	Male	19	91	17.3	0.90
	Female	6	27	18.2
Performance status	0–1	25	98	20.3	0.026
	2–3	0	20	0.0
BMI (kg/m2)	<20	11	57	16.2	0.70
	≥20	14	61	18.7
Histology*	Differentiated	16	77	17.2	0.89
	Undifferentiated	8	41	16.3
History of gastrectomy	Yes	18	66	21.4	0.14
	No	7	52	11.9
Number of previous chemotherapy regimens	2	14	66	17.5	0.64
	3	6	36	14.3
	≥4	5	16	23.8
Liver metastasis	Yes	7	49	12.5	0.21
	No	18	69	20.7
Lung metastasis	Yes	2	10	16.7	0.94
	No	23	108	17.6
Lymph node metastasis	Yes	16	63	20.3	0.33
	No	9	55	14.1
Peritoneum metastasis	Yes	3	42	6.7	0.021
	No	22	76	22.4
NLR	<2.4	11	58	15.9	0.64
	≥2.4	14	60	18.9
CRP (mg/dL)*	<1.0	21	78	21.2	0.087
	≥1.0	4	39	9.3
PD-L1 TPS	<1	14	94	13.0	0.012
	≥1	11	24	31.4
PD-L1 CPS	<1	6	49	10.9	0.10
	≥1	19	69	21.6
PD-L1 CPS	<5	10	81	11.0	0.007
	≥5	15	37	28.8
PD-L1 CPS	<10	12	99	10.8	<0.001
	≥10	13	19	40.6
MMR	Proficient	15	107	12.3	<0.001
	Deficient	10	11	47.6

^*Data not available for one patient.

BMI body mass index, NLR neutrophil-to-lymphocyte ratio, CRP C-reactive protein, PD-L1 programmed death-ligand 1, TPS tumour-positive score, CPS combined positive score, MMR mismatch repair.